Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „safety“
Suchtreffer
Begriffe & Kennungen
Adempas · 4.8 · The safety of riociguat has been investigated in 24 paediatric patients aged 6 to less than 18 years over 24 w
Eintrag öffnenAdempas · 4.8 · The safety of riociguat has been investigated in 24 paediatric patients aged 6 to less than 18 years over 24 w
Eintrag öffnenAdempas · 4.8 · The safety of riociguat in adults has been evaluated in phase III studies of 650 patients patients with CTEPH
Eintrag öffnenAdempas · 4.8 · The safety of riociguat in adults has been evaluated in phase III studies of 650 patients with CTEPH and PAH r
Eintrag öffnenAdempas · 4.8 · The safety profile of riociguat in patients with CTEPH and PAH appeared to be similar, therefore adverse react
Eintrag öffnenAdempas · 4.8 · The safety profile of riociguat in patients with CTEPH and PAH appeared to be similar, therefore adverse react
Eintrag öffnenAdenuric · 4.8 · Summary of the safety profile The most commonly reported adverse reactions in clinical trials (4,072 subjects
Eintrag öffnenAdenuric · 4.8 · Summary of the safety profile The most commonly reported adverse reactions in clinical trials (4,072 subjects
Eintrag öffnenAdenuric · 4.8 · Table 1: Adverse reactions in combined phase 3, long-term extension studies, post-authorisation safety studies
Eintrag öffnenAdenuric · 4.8 · Table 1: Adverse reactions in combined phase 3, long-term extension studies, post-authorisation safety studies
Eintrag öffnenAdenuric · 4.8 · Tumor Lysis Syndrome Summary of the safety profile In the randomized, double-blind, Phase 3 pivotal FLORENCE (
Eintrag öffnenAdjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) · 4.8 · Data for this age group is derived from a pooling of safety data from 2 studies (D-PAN-H5N1-032 and Q-PAN-H5N1
Eintrag öffnenAdjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) · 4.8 · Data for this age group is derived from a pooling of safety data from 3 studies (D-PAN-H5N1-013, Q-PAN-H5N1-02
Eintrag öffnenAdjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) · 4.8 · Summary of the safety profile
Eintrag öffnenAdrovance · 4.8 · Summary of the safety profile The most commonly reported adverse reactions are upper gastrointestinal adverse
Eintrag öffnenAdtralza · 4.5 · The safety and efficacy of concurrent use of tralokinumab with live and live attenuated vaccines has not been
Eintrag öffnenAdtralza · 4.8 · Anti-drug-antibody (ADA) responses were not associated with any impact on tralokinumab exposure, safety, or ef
Eintrag öffnenAdtralza · 4.8 · Summary of the safety profile
Eintrag öffnenAdtralza · 4.8 · The long-term safety of tralokinumab was assessed in 2 monotherapy studies up to 52 weeks, and in a combinatio
Eintrag öffnenAdtralza · 4.8 · The safety of tralokinumab was assessed in patients 12 to 17 years of age (adolescents) with moderate-to-sever
Eintrag öffnen